IGF-1 LR3 – 1MG

IGF-1 LR3 (1mg) — Research Compound

IGF-1 LR3 (Long Arginine 3-IGF-1) is a synthetic analogue of human Insulin-like Growth Factor-1 (IGF-1), modified to include an additional 13 amino acids and a substitution at the third position. This modification significantly reduces its binding to IGF-binding proteins (IGFBPs), resulting in a much longer half-life and higher biological potency. Researchers study IGF-1 LR3 for its role in cellular proliferation, muscle hypertrophy, and its ability to stimulate the transport of amino acids and glucose into muscle cells.

Findings from early-stage clinical trials have reported:

• Marked increases in muscle cell hyperplasia (the growth of new muscle cells) observed in research models
  
• Significant improvements in nitrogen retention and protein synthesis rates reported in-vivo
  
• Enhanced glucose uptake and improved nutrient partitioning noted across experimental cohorts
  
• Sustained elevations in systemic anabolic activity observed due to reduced protein binding
  

Researchers study IGF-1 LR3 to investigate the limits of myogenic development and the regulation of cellular growth pathways. Its extended half-life allows for the study of continuous IGF-1 receptor activation, making it a specialized tool for understanding muscle wasting, tissue regeneration, and the biological response to chronic anabolic signaling. It is a primary focus for research into the preservation of lean mass and the recovery of skeletal muscle function.

Available Formats:
This compound is available as a vial of lyophilised powder, or can be ordered in a disposable pen, a reusable pen, or a cartridge for an existing reusable pen system.

Used solely for in vitro experiments and cannot be:

• Used in clinical trials involving humans
• Administered to humans as part of an experiment or investigation
• Supplied to another party for human investigational use